1 completed, 1 terminated. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Terminated 1 |
Follow cannabigerol: new trials by email Literature Review of cannabigerol trials Research Report on cannabigerol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder Cannabigerol, Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 2 | Completed | University of Arkansas, Fayetteville | 67 | 2024-12-14 | 2026-11-09 |
| Cannabidiol 133mg + Cannabigerol 66mg + Tetrahydrocannabinol 4mg Vs Placebo As Adjuvant Treatment in Chronic Migraine - Placebo oral drops, Cannabidiol + Cannabigerol + Tetrahydrocannabinol 133/66/4mg - Chronic Migraine, Headache, Overuse Headache Medication | Phase 2 / Phase 3 | Terminated | Hospital Israelita Albert Einstein | 110 | 2022-10-18 | 2025-02-24 |
Attention Deficit Disorder with Hyperactivity (1) · Headache (1) · Headache Disorders, Secondary (1)
Hospital Israelita Albert Einstein (1) · University of Arkansas, Fayetteville (1)
Brazil (1) · United States (1)
Alexandre O Kaup, MD, PhD (1) · Ellen W Leen-Feldner, PhD (1)